
Chanson J Brumme

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8484587/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses. Journal of Infectious Diseases, 2023, 227, 838-849.	1.9	31
2	Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study. Journal of Antimicrobial Chemotherapy, 2022, 77, 979-988.	1.3	7
3	Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. Journal of Infectious Diseases, 2022, 225, 1129-1140.	1.9	65
4	Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. Npj Vaccines, 2022, 7, 28.	2.9	64
5	A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies. Journal of Experimental Medicine, 2021, 218, .	4.2	9
6	Intra-host evolutionary dynamics of the hepatitis C virus among people who inject drugs. Scientific Reports, 2021, 11, 9986.	1.6	1
7	Rapid Detection of SARS-CoV-2 Variants of Concern, Including B.1.1.28/P.1, British Columbia, Canada. Emerging Infectious Diseases, 2021, 27, 1673-1676.	2.0	38
8	Proviral Turnover During Untreated HIV Infection Is Dynamic and Variable Between Hosts, Impacting Reservoir Composition on ART. Frontiers in Microbiology, 2021, 12, 719153.	1.5	8
9	Validation of a Genotype-Independent Hepatitis C Virus Near-Whole Genome Sequencing Assay. Viruses, 2021, 13, 1721.	1.5	1
10	SARS-CoV-2 RNA Quantification Using Droplet Digital RT-PCR. Journal of Molecular Diagnostics, 2021, 23, 907-919.	1.2	17
11	Understanding patterns of HIV multi-drug resistance through models of temporal and spatial drug heterogeneity. ELife, 2021, 10, .	2.8	27
12	Concordance of HIV transmission risk factors elucidated using viral diversification rate and phylogenetic clustering. Evolution, Medicine and Public Health, 2021, 9, 338-348.	1.1	5
13	Untimed Efavirenz Drug Levels After Switching From Brand to Generic Formulations: A Short Communication. Therapeutic Drug Monitoring, 2021, 43, 701-705.	1.0	1
14	HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA). Nature Communications, 2021, 12, 165.	5.8	60
15	HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy. MBio, 2021, 12, e0249021.	1.8	14
16	Variation in HIV-1 Nef function within and among viral subtypes reveals genetically separable antagonism of SERINC3 and SERINC5. PLoS Pathogens, 2020, 16, e1008813.	2.1	20
17	Genetic Diversity, Compartmentalization, and Age of HIV Proviruses Persisting in CD4 ⁺ T Cell Subsets during Long-Term Combination Antiretroviral Therapy. Journal of Virology, 2020, 94, .	1.5	21
18	Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	1

#	Article	IF	CITATIONS
19	Differential Vpu-Mediated CD4 and Tetherin Downregulation Functions among Major HIV-1 Group M Subtypes. Journal of Virology, 2020, 94, .	1.5	6
20	Are We Ready for NGS HIV Drug Resistance Testing? The Second "Winnipeg Consensus―Symposium. Viruses, 2020, 12, 586.	1.5	18
21	The Impact of Treatment as Prevention on the HIV Epidemic in British Columbia, Canada. Current HIV/AIDS Reports, 2020, 17, 77-87.	1.1	16
22	Suboptimal Biological Sampling as a Probable Cause of False-Negative COVID-19 Diagnostic Test Results. Journal of Infectious Diseases, 2020, 222, 899-902.	1.9	75
23	Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping. Viruses, 2020, 12, 694.	1.5	34
24	Longitudinal within-host evolution of HIV Nef-mediated CD4, HLA and SERINC5 downregulation activity: a case study. Retrovirology, 2020, 17, 3.	0.9	10
25	Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing. Scientific Reports, 2020, 10, 1634.	1.6	45
26	Evaluation of Nasopharyngeal Swab Collection Techniques for Nucleic Acid Recovery and Participant Experience: Recommendations for COVID-19 Diagnostics. Open Forum Infectious Diseases, 2020, 7, ofaa488.	0.4	21
27	T-cell responses to sequentially emerging viral escape mutants shape long-term HIV-1 population dynamics. PLoS Pathogens, 2020, 16, e1009177.	2.1	4
28	Title is missing!. , 2020, 16, e1009177.		0
29	Title is missing!. , 2020, 16, e1009177.		0
30	Title is missing!. , 2020, 16, e1009177.		0
31	Title is missing!. , 2020, 16, e1009177.		0
32	Detection of HIV transmission hotspots in British Columbia, Canada: A novel framework for the prioritization and allocation of treatment and prevention resources. EBioMedicine, 2019, 48, 405-413.	2.7	8
33	Rates and Correlates of Short Term Virologic Response among Treatment-NaÃ ⁻ ve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study. Pathogens, 2019, 8, 161.	1.2	4
34	Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia. Viruses, 2019, 11, 877.	1.5	9
35	Intra- and inter-individual HIV diversity limits the application of the intact proviral detection assay (IPDA). Journal of Virus Eradication, 2019, 5, 9.	0.3	0
36	HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals. Journal of Virology, 2019, 93, .	1.5	32

#	Article	IF	CITATIONS
37	A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections. Infection, Genetics and Evolution, 2019, 69, 76-84.	1.0	6
38	Genotypic and Mechanistic Characterization of Subtype-Specific HIV Adaptation to Host Cellular Immunity. Journal of Virology, 2019, 93, .	1.5	17
39	Novel HLA class I associations with HIV-1 control in a unique genetically admixed population. Scientific Reports, 2018, 8, 6111.	1.6	32
40	Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa. Antiviral Chemistry and Chemotherapy, 2018, 26, 204020661876298.	0.3	6
41	Longitudinal trends of HIV drug resistance in a large Canadian cohort, 1996–2016. Clinical Microbiology and Infection, 2018, 24, 185-191.	2.8	33
42	Weaker HLA Footprints on HIV in the Unique and Highly Genetically Admixed Host Population of Mexico. Journal of Virology, 2018, 92, .	1.5	5
43	Bioinformatic data processing pipelines in support of nextâ€generation sequencingâ€based <scp>HIV</scp> drug resistance testing: the Winnipeg Consensus. Journal of the International AIDS Society, 2018, 21, e25193.	1.2	34
44	High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia. Viruses, 2018, 10, 60.	1.5	11
45	Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South Africa. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	12
46	Mother-to-Child HIV Transmission Bottleneck Selects for Consensus Virus with Lower Gag-Protease-Driven Replication Capacity. Journal of Virology, 2017, 91, .	1.5	13
47	Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load. Journal of Antimicrobial Chemotherapy, 2017, 72, 496-503.	1.3	5
48	Promises and pitfalls of Illumina sequencing for HIV resistance genotyping. Virus Research, 2017, 239, 97-105.	1.1	27
49	Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by near-full-genome population and deep sequencing approaches. Aids, 2017, 31, 2345-2354.	1.0	23
50	Estimating the Respective Contributions of Human and Viral Genetic Variation to HIV Control. PLoS Computational Biology, 2017, 13, e1005339.	1.5	28
51	Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification. PLoS ONE, 2017, 12, e0171155.	1.1	7
52	Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada. PLoS ONE, 2017, 12, e0184848.	1.1	5
53	Impact of pre-adapted HIV transmission. Nature Medicine, 2016, 22, 606-613.	15.2	87
54	Increasing prevalence of K65K and K66K in HIV-1 subtype B reverse transcriptase. Aids, 2016, 30, 2787-2793.	1.0	1

#	Article	IF	CITATIONS
55	Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals. Retrovirology, 2015, 12, 98.	0.9	4
56	Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir. Journal of Clinical Microbiology, 2015, 53, 2942-2950.	1.8	11
57	The Impact of Clinical, Demographic and Risk Factors on Rates of HIV Transmission: A Population-based Phylogenetic Analysis in British Columbia, Canada. Journal of Infectious Diseases, 2015, 211, 926-935.	1.9	89
58	HIV Drug Resistance Testing by High-Multiplex "Wide―Sequencing on the MiSeq Instrument. Antimicrobial Agents and Chemotherapy, 2015, 59, 6824-6833.	1.4	50
59	Limited Evolution of Inferred HIV-1 Tropism while Viremia Is Undetectable during Standard HAART Therapy. PLoS ONE, 2014, 9, e99000.	1.1	7
60	Competitive Fitness Assays Indicate that the E138A Substitution in HIV-1 Reverse Transcriptase DecreasesIn VitroSusceptibility to Emtricitabine. Antimicrobial Agents and Chemotherapy, 2014, 58, 2430-2433.	1.4	8
61	Genotypic and Functional Impact of HIV-1 Adaptation to Its Host Population during the North American Epidemic. PLoS Genetics, 2014, 10, e1004295.	1.5	45
62	Theoretical and experimental assessment of degenerate primer tagging in ultra-deep applications of next-generation sequencing. Nucleic Acids Research, 2014, 42, e98-e98.	6.5	29
63	Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NFκB. Retrovirology, 2014, 11, 17.	0.9	37
64	Prevalence and Virologic Consequences of Transmitted HIV-1 Drug Resistance in Uganda. AIDS Research and Human Retroviruses, 2014, 30, 896-906.	0.5	26
65	Subtype-Specific HIV-1 Adaptation to Host HLA. AIDS Research and Human Retroviruses, 2014, 30, A218-A218.	0.5	Ο
66	Transmitted Escape Mutations Lead to Accelerated HIV-1 Disease Progression and Largely Define the Relative Contribution of HLA Alleles to Control. AIDS Research and Human Retroviruses, 2014, 30, A40-A40.	0.5	0
67	Trends in Plasma HIV-RNA Suppression and Antiretroviral Resistance in British Columbia, 1997–2010. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 107-114.	0.9	14
68	Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes. Retrovirology, 2013, 10, 100.	0.9	68
69	Influence of HLA-C Expression Level on HIV Control. Science, 2013, 340, 87-91.	6.0	352
70	"Test-and-Treat―Strategy for Control of HIV and AIDS Can Lead to a Decrease, Not an Increase, of Multidrug-Resistant Viruses. Clinical Infectious Diseases, 2013, 57, 478-479.	2.9	3
71	Structure of TCR and antigen complexes at an immunodominant CTL epitope in HIV-1 infection. Scientific Reports, 2013, 3, 3097.	1.6	35
72	Replication Fitness of Multiple Nonnucleoside Reverse Transcriptase-Resistant HIV-1 Variants in the Presence of Etravirine Measured by 454 Deep Sequencing. Journal of Virology, 2013, 87, 8805-8807.	1.5	9

#	Article	IF	CITATIONS
73	Genotypic Analysis of the V3 Region of HIV from Virologic Nonresponders to Maraviroc-Containing Regimens Reveals Distinct Patterns of Failure. Antimicrobial Agents and Chemotherapy, 2013, 57, 6122-6130.	1.4	17
74	A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. ELife, 2013, 2, e01123.	2.8	126
75	Whole Genome Deep Sequencing of HIV-1 Reveals the Impact of Early Minor Variants Upon Immune Recognition During Acute Infection. PLoS Pathogens, 2012, 8, e1002529.	2.1	306
76	Automating HIV Drug Resistance Genotyping with RECall, a Freely Accessible Sequence Analysis Tool. Journal of Clinical Microbiology, 2012, 50, 1936-1942.	1.8	156
77	Correlates of Protective Cellular Immunity Revealed by Analysis of Population-Level Immune Escape Pathways in HIV-1. Journal of Virology, 2012, 86, 13202-13216.	1.5	99
78	Aminopeptidase Substrate Preference Affects HIV Epitope Presentation and Predicts Immune Escape Patterns in HIV-Infected Individuals. Journal of Immunology, 2012, 188, 5924-5934.	0.4	30
79	Uncommon Pathways of Immune Escape Attenuate HIV-1 Integrase Replication Capacity. Journal of Virology, 2012, 86, 6913-6923.	1.5	33
80	Increasingly Successful Highly Active Antiretroviral Therapy Delays the Emergence of New HLA Class I–Associated Escape Mutations in HIV-1. Clinical Infectious Diseases, 2012, 54, 1652-1659.	2.9	11
81	Population-Based Sequencing of the V3-loop Can Predict the Virological Response to Maraviroc in Treatment-Naive Patients of the MERIT Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 279-286.	0.9	41
82	Minor contribution of HLA class I-associated selective pressure to the variability of HIV-1 accessory protein Vpu. Biochemical and Biophysical Research Communications, 2012, 421, 291-295.	1.0	9
83	Characteristics and Outcomes of Initial Virologic Suppressors during Analytic Treatment Interruption in a Therapeutic HIV-1 gag Vaccine Trial. PLoS ONE, 2012, 7, e34134.	1.1	5
84	Technical and Regulatory Shortcomings of the TaqMan Version 1 HIV Viral Load Assay. PLoS ONE, 2012, 7, e43882.	1.1	13
85	Reduced Replication Capacity of NL4-3 Recombinant Viruses Encoding Reverse Transcriptase–Integrase Sequences From HIV-1 Elite Controllers. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 100-108.	0.9	59
86	Definition of the viral targets of protective HIV-1-specific T cell responses. Journal of Translational Medicine, 2011, 9, 208.	1.8	143
87	Influence of Gag-Protease-Mediated Replication Capacity on Disease Progression in Individuals Recently Infected with HIV-1 Subtype C. Journal of Virology, 2011, 85, 3996-4006.	1.5	50
88	Factors Associated With Viral Rebound in HIV-1-Infected Individuals Enrolled in a Therapeutic HIV-1 gag Vaccine Trial. Journal of Infectious Diseases, 2011, 203, 976-983.	1.9	29
89	Quantitative Trait Loci for CD4:CD8 Lymphocyte Ratio Are Associated with Risk of Type 1 Diabetes and HIV-1 Immune Control. American Journal of Human Genetics, 2010, 86, 88-92.	2.6	80
90	Viral adaptation to immune selection pressure by HLA class l–restricted CTL responses targeting epitopes in HIV frameshift sequences. Journal of Experimental Medicine, 2010, 207, 61-75.	4.2	52

#	Article	IF	CITATIONS
91	Impaired Replication Capacity of Acute/Early Viruses in Persons Who Become HIV Controllers. Journal of Virology, 2010, 84, 7581-7591.	1.5	118
92	Gag-Protease-Mediated Replication Capacity in HIV-1 Subtype C Chronic Infection: Associations with HLA Type and Clinical Parameters. Journal of Virology, 2010, 84, 10820-10831.	1.5	87
93	Early Selection in Gag by Protective HLA Alleles Contributes to Reduced HIV-1 Replication Capacity That May Be Largely Compensated for in Chronic Infection. Journal of Virology, 2010, 84, 11937-11949.	1.5	111
94	Efficacious Early Antiviral Activity of HIV Gag- and Pol-Specific HLA-B*2705-Restricted CD8 + T Cells. Journal of Virology, 2010, 84, 10543-10557.	1.5	84
95	The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. Science, 2010, 330, 1551-1557.	6.0	1,054
96	HLA-Associated Viral Mutations Are Common in Human Immunodeficiency Virus Type 1 Elite Controllers. Journal of Virology, 2009, 83, 3407-3412.	1.5	67
97	Transmission and Long-Term Stability of Compensated CD8 Escape Mutations. Journal of Virology, 2009, 83, 3993-3997.	1.5	58
98	HLA-Associated Alterations in Replication Capacity of Chimeric NL4-3 Viruses Carrying <i>gag-protease</i> from Elite Controllers of Human Immunodeficiency Virus Type 1. Journal of Virology, 2009, 83, 140-149.	1.5	112
99	Human Immunodeficiency Virus Type 1-Specific CD8 ⁺ T-Cell Responses during Primary Infection Are Major Determinants of the Viral Set Point and Loss of CD4 ⁺ T Cells. Journal of Virology, 2009, 83, 7641-7648.	1.5	173
100	Impact of Select Immunologic and Virologic Biomarkers on CD4 Cell Count Decrease in Patients with Chronic HIVâ€I Subtype C Infection: Results from Sinikithemba Cohort, Durban, South Africa. Clinical Infectious Diseases, 2009, 49, 956-964.	2.9	19
101	HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphotye Recognition. Journal of Virology, 2009, 83, 2743-2755.	1.5	261
102	Adaptation of HIV-1 to human leukocyte antigen class I. Nature, 2009, 458, 641-645.	13.7	408
103	HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag, Pol and Nef Proteins. PLoS ONE, 2009, 4, e6687.	1.1	148
104	Marked Epitope- and Allele-Specific Differences in Rates of Mutation in Human Immunodeficiency Type 1 (HIV-1) Gag, Pol, and Nef Cytotoxic T-Lymphocyte Epitopes in Acute/Early HIV-1 Infection. Journal of Virology, 2008, 82, 9216-9227.	1.5	162
105	CD4-Dependent Characteristics of Coreceptor Use and HIV Type 1 V3 Sequence in a Large Population of Therapy-Naive Individuals. AIDS Research and Human Retroviruses, 2008, 24, 219-228.	0.5	23
106	Phylogenetic Dependency Networks: Inferring Patterns of CTL Escape and Codon Covariation in HIV-1 Gag. PLoS Computational Biology, 2008, 4, e1000225.	1.5	116
107	Genetic Characterization of Human Immunodeficiency Virus Type 1 in Elite Controllers: Lack of Gross Genetic Defects or Common Amino Acid Changes. Journal of Virology, 2008, 82, 8422-8430.	1.5	114
108	Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection. Aids, 2008, 22, 1277-1286.	1.0	67

#	Article	IF	CITATIONS
109	The Relationship Between Resistance and Adherence in Drug-Naive Individuals Initiating HAART Is Specific to Individual Drug Classes. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 266-271.	0.9	52
110	Antigen Load and Viral Sequence Diversification Determine the Functional Profile of HIV-1–Specific CD8+ T Cells. PLoS Medicine, 2008, 5, e100.	3.9	205
111	Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1. PLoS Pathogens, 2007, 3, e94.	2.1	153
112	Reply to Waters et al Clinical Infectious Diseases, 2007, 45, 1244-1245.	2.9	0
113	A Simple Screening Approach to Reduce B*5701-Associated Abacavir Hypersensitivity on the Basis of Sequence Variation in HIV Reverse Transcriptase. Clinical Infectious Diseases, 2007, 44, 1503-1508.	2.9	35
114	Effects of Human Leukocyte Antigen Class I Genetic Parameters on Clinical Outcomes and Survival after Initiation of Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2007, 195, 1694-1704.	1.9	31
115	Transmission of drug-resistant HIV-1 from an infected individual to a caregiver. Antiviral Therapy, 2007, 12, 1139-44.	0.6	1
116	Transmission of Drug-Resistant HIV-1 from an Infected Individual to a Caregiver. Antiviral Therapy, 2007, 12, 1139-1144.	0.6	3
117	Short Communication: HIV VprR77Q Mutation Does Not Influence Clinical Response of Individuals Initiating Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2006, 22, 615-618.	0.5	13
118	Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. Aids, 2005, 19, 1189-1195.	1.0	42
119	Molecular and Clinical Epidemiology of CXCR4â€Using HIVâ€1 in a Large Population of Antiretroviralâ€Naive Individuals. Journal of Infectious Diseases, 2005, 192, 466-474.	1.9	260
120	No Inherent Association between Minor Mutations in HIV Protease at Baseline and Selection of the L90M Mutation at the Time of the First Virological Failure. Journal of Infectious Diseases, 2005, 191, 1778-1779.	1.9	5
121	Predictors of HIV Drugâ€Resistance Mutations in a Large Antiretroviralâ€Naive Cohort Initiating Triple Antiretroviral Therapy. Journal of Infectious Diseases, 2005, 191, 339-347.	1.9	386
122	HIVâ€1 Drug Resistance: Degree of Underestimation by a Crossâ€Sectional versus a Longitudinal Testing Approach. Journal of Infectious Diseases, 2005, 191, 1325-1330.	1.9	42
123	Association of the CCR5Δ32 Mutation with Clinical Response and >5-year Survival following Initiation of First Triple Antiretroviral Regimen. Antiviral Therapy, 2005, 10, 849-853.	0.6	7
124	A Participant-Derived Xenograft Model of HIV Enables Long-Term Evaluation of Autologous Immunotherapies. SSRN Electronic Journal, 0, , .	0.4	1